<DOC>
	<DOCNO>NCT01296386</DOCNO>
	<brief_summary>An open-label Phase 1 Study Assessing Safety , Immunogenicity Dose Response IC84 , A new vaccine Clostridium Difficile ( C. difficile ) , In healthy subject</brief_summary>
	<brief_title>An Open-label Study Assessing Safety , Immunogenicity Dose Response IC84</brief_title>
	<detailed_description>This open-label , partially randomize , dose escalation Phase 1 study consist part A healthy adult age ≥18 &lt; 65 year part B healthy elderly ≥65 year , latter age group vulnerable population suffer C. difficile infection . Part A consist 3 vaccination Day0 , Day7 Day21 follow group : Group A : IC84 20 mcg ( microgram ) Alum Group B : IC84 75 mcg ( microgram ) Alum Group C : IC84 75 mcg ( microgram ) without Alum Group D : IC84 200 mcg ( microgram ) Alum Group E : IC84 200 mcg ( microgram ) without Alum Part A already finish part B ongoing . All information could find section refer information Part B .</detailed_description>
	<criteria>1 . Healthy adult ≥18 year age . 2 . No clinically relevant pathological finding investigation Screening Visit include subject pharmacologically control condition like hypercholesterolemia , hypertension , cardiovascular disease non insulindependent diabetes mellitus . Minor deviation laboratory value normal range may accept , judge investigator clinical relevance . 3 . In female subject , either childbearing potential terminate surgery 1 year post menopausal , negative serum pregnancy test screen willingness become pregnant entire study period practice reliable method contraception . 4 . Weight : ≥ 45.5 kg &lt; = 150 kg Visit 0 ( Screening Visit ) . 5 . White blood cell ≥2,500/mm3 &lt; 11,000/mm3 Visit 0 . 6 . Platelets within normal limit Visit 0 . 7 . Written inform consent obtain subject prior study related procedure . 1 . Use investigational nonregistered medicinal product within 30 day prior IC84 vaccination Visit 1 ( Day 0 ) throughout entire study period . 2 . Active passive vaccination four week first vaccination Visit 1 entire study period . 3 . Immunodeficiency include status postorgantransplantation immunosuppressive therapy , family history congenital hereditary immunodeficiency . 4 . Infection human immunodeficiency virus ( HIV , negative test result within 30 day screen acceptable ) , Hepatitis B virus ( HBV , Hepatitis B surface antigen [ HBsAg ] ) Hepatitis C virus ( HCV ) . 5 . History severe hypersensitivity reaction anaphylaxis . 6 . History allergic bronchial asthma severe allergic rhinoconjunctivitis . 7 . Known hypersensitivity allergic reaction one component vaccine . 8 . History autoimmune disease , include Type I Diabetes mellitus . Subjects vitiligo thyroid disease take thyroid hormone replacement exclude . 9 . Any malignancy past 5 year . If treatment cancer successfully complete 5 year ago malignancy consider cure , subject may enrol . 10 . Clinically significant hematological , renal , hepatic , pulmonary , central nervous , cardiovascular gastrointestinal disorder , adequately control medical treatment within last 12 week IC84 vaccination Visit 1 ( Day 0 ) judge site 's Principal Investigator . 11 . Systemic antibiotic use within four week prior first vaccination treatment period ( Day 28 ) . 12 . Clinically significant disease judge investigator . 13 . Administration chronic ( define longer 14 day ) immunosuppressant immunemodifying drug within 30 day prior IC84 vaccination Visit 1 ( Day 0 ) study Visit 5 ( Day 28 ) . ( For corticosteroid mean prednisone equivalent &gt; = 0.05 mg/kg/day ; topical inhale steroid allowed. ) . 14 . Periodic steroid injection , e.g. , intraarticular , allow within 30 day prior first IC84 vaccination Visit 1 ( Day 0 ) Visit 5 ( Day 28 ) . 15 . Intake NSAID within three day prior within three day three vaccination ( Day 0 , 7 21 ) . 16 . Acute febrile infection exacerbation chronic infection within four week prior first vaccination Visit 1 treatment period ( Day 21 ) . 17 . Body temperature &gt; 37°C ( oral ) immediately prior vaccination . 18 . Drug addiction within 6 month prior Visit 0 [ include alcohol dependence , i.e . approximately 60 g alcohol ( approximately 1 liter beer 0.5 liter wine ) per day ] indicate elevated MCV normal value Screening Visit . 19 . Inability unwillingness avoid usual intake alcohol [ i.e. , 60 g alcohol ( approximately 1 liter beer 0.5 liter wine ) per day ] 48 hour vaccination . 20 . Pregnancy ( positive pregnancy test screening ) , lactation unreliable contraception female subject childbearing potential ( unreliable contraception male subject . 21 . Not able understand comply protocol requirement , instruction protocolstated restriction . 22 . Blood donation within 4 week prior first vaccination . 23 . Clinically significant mental disorder adequately control medical treatment . 24 . History GuillainBarréSyndrome ( GBS ) . 25 . Any condition might interfere study objective would limit subject 's ability complete study opinion investigator . 26 . Inability unwillingness provide inform consent . 27 . Persons committed institution ( virtue order issue either judicial administrative authority ) .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>